(P049) Increased Portal Venous Enhancement of Hepatocellular Carcinoma Following Transcatheter Arterial Chemoembolization

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

The majority of cases exhibited increased enhancement on portal venous phase following treatment with TACE, demonstrating the importance of surveillance with proper multiphase imaging to assess for recurrence, especially in light of a decrease in arterial phase enhancement following treatment.

Alexander Lam, MD, Megha Nayyar, BS, Chandana Lall, MD; UCI Medical Center

Hepatocellular carcinoma (HCC) is a growing cause of mortality throughout the United States, despite advancements in diagnosis and treatment. As advanced HCC progresses, it becomes more dependent on arterial blood. This translates to the typical imaging characteristics of sharp contrast enhancement during arterial phase, followed by brisk portal venous washout on multiphasic computed tomography (CT). Liver-directed therapies, such as transarterial chemoembolization (TACE), have utilized this preferential arterial flow to administer targeted chemotherapy agents and embolize parasitized arterial branches.

By compromising arterial flow, these embolic therapies alter the imaging characteristics that are typically dependent on hemodynamics, such as multiphasic CT. We hypothesize that the portal venous supply to the tumor experiences a sustained, compensatory increase following chemoembolization, resulting in increased enhancement on portal venous phase when compared with the pretreatment tumor bed. To evaluate this hypothesis, the images of 102 patients with advanced HCC were retrospectively reviewed by two fellowship-trained radiologists. Appropriate preprocedural and posttreatment CT images were performed at noncontrast, arterial, and portal venous phases. Digital subtraction angiographic images were reviewed to confirm the target lesion for evaluation and ensure adequate obliteration of the arterial vessels feeding the tumor. Degree of enhancement was quantified by drawing a circular region of interest (ROI) within the lesion margin of at least 1 cm2. Differences in attenuation of the tumor bed were standardized against normal liver parenchyma and underlying background on the same slice. Enhancement was defined as a difference greater than 15 Hounsfield units (HU) from baseline attenuation on the noncontrast study. Enhancement patterns among the phases were compared between the pre- and posttreatment scans.

A total of 50% (51 out of 102) of HCC cases following TACE demonstrated definite increased enhancement on venous phase compared with the preprocedural images, of which the majority consisted of increased peripheral enhancement. Arterial enhancement was decreased or unchanged for these patients. Also, 24% of cases (25 patients) showed unchanged enhancement on arterial phase images following TACE therapy, with no change in the appropriate venous washout. A total of 11% of cases (11 patients) showed unchanged enhancement on both arterial and portal venous phase after therapy, and 15% of cases (15 patients) demonstrated increased enhancement on arterial phase and not on venous phase.

The majority of cases exhibited increased enhancement on portal venous phase following treatment with TACE, demonstrating the importance of surveillance with proper multiphase imaging to assess for recurrence, especially in light of a decrease in arterial phase enhancement following treatment.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content